Investing.com -- Alteogen shares plunged as much as 12% on the Kosdaq exchange on Friday, marking the stock’s biggest drop in more than a year, after its partner Merck faced a legal setback in Germany.
The sharp decline made Alteogen the worst performer in the MSCI Asia Pacific Index on Friday.
The selloff came after Halozyme Therapeutics announced that a German court granted its request for a preliminary injunction against Merck.
The court order requires Merck to halt the distribution and offering of Keytruda SC, a cancer drug, in Germany.
The legal decision represents a significant blow to Merck’s distribution plans for the cancer treatment in the German market, directly impacting Alteogen as Merck’s partner in the venture.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.








